NCT03320434View on ClinicalTrials.gov

Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 13, 2017

Primary Completion Date

February 16, 2018

Study Completion Date

February 18, 2018

Conditions
Allergic Conjunctivitis
Interventions
DRUG

PRT-2761 0.5%

Six drops in each eye over a 17 day period.

DRUG

PRT-2761 1%

Six drops in each eye over a 17 day period.

DRUG

Patanol

Six drops in each eye over a 17 day period.

DRUG

Pred-forte

Four drops in each eye over a 3 day period.

DRUG

PRT-2761 0%

Six drops in each eye over a 17 day period.

Trial Locations (1)

01810

Andover Eye Associates, Andover

All Listed Sponsors
lead

ORA, Inc.

INDUSTRY

NCT03320434 - Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis | Biotech Hunter | Biotech Hunter